Autologous reinfusion of peripheral blood mononuclear (n = 6) and multiple myeloma (n = 1) by leukapheresis cells (PBMNC) after high-dose chemotherapy constitutes using an automated MNC separation system and conan important alternative to autologous bone marrow transtaminated with 1% (n = 5) or 10% (n = 2) tumor cells plantation in patients with hematologic malignancies or from different epithelial cell lines being CD34-negative.
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The cell mixture was sensitized with anti-CD34 (9C5)
There are multiple advantages of PBMNC reinfusion vs antibodies and sheep anti-mouse IgG1 paramagnetic autologous bone marrow transplants. The collection promicrospheres and enriched for CD34
؉ cells using an cedure with a central i.v. line is much easier abrogating any Isolex 50 magnetic separator. Purity of CD34
؉ cells was need for general anesthesia for the donor. Hematological studied by flow cytometry (FACScan) and tumor cell reconstitution in the recipient is faster 4-7 which contributes depletion was evaluated by comparative human tumor to applicability of high-dose protocols. cloning assays (HTCA) containing methylcellulose and Although the rate of tumor cell contamination in agar. We achieved a median purity of CD34 ؉ cells of PBMNC has been reported to be significantly lower than 85.9% (range 69.8-92.9%) and a median yield of 48. 1% in bone marrow transplants 8 the circulation of tumor cells (range 21.0-85.2%). From these data in each case the in the PBMNC transplant remains a major concern regardestimated log depletion of tumor cells was calculated ing the prognosis of patients. [9] [10] [11] [12] [13] [14] [15] [16] Brenner et al 15 showed and compared with the experimentally achieved with genetic markers that residual tumor cells in autologous (HTCA) log depletion (log ⌬ depletion = log experibone marrow transplants can contribute to disease recurmental depletion − log calculated depletion). In our rence. Moreover, mobilization of hematopoietic stem cells experiments we achieved a median depletion of 2.75 log into peripheral blood by applying chemotherapy followed (range 1.
55-3.69 log). When corrected for CD34
؉ cell by G-CSF was found to have a similar effect on the yield of each experiment we observed a median 'yield mobility of tumor cells.
17 corrected depletion' of 2.38 log (range 1.48-3.15 log). Different techniques of purging tumor cells have been The following ⌬ depletion values were obtained: ؉0. 32 developed and are currently under investigation with the log (HTB 129, breast), ؉0.21 log (HTB 26, breast), focus on chemical or pharmacological [18] [19] [20] and immuno-؉0.04 log (HTB 26) for experiments with higher experimagnetic methods. 21, 22 Since the CD34 antigen has not mental depletion, and −0.23 log (HTB 26), −0.9 log been detected in most solid tumors, 23 positive selection of (HTB 26, PBMNC from patient with multiple CD34 + cells from tumor contaminated peripheral blood myeloma), −0.82 log (HTB 131, breast) and −1.66 log mononuclear cell collections may represent an alternative (HTB 131) for lower depletion efficacy than calculated.
purging strategy prior to autologous reinfusion. These data suggest that depletion may depend on spe-
In this paper we evaluate the efficiency of purging tumor cific cell surface characteristics of tumor cells. Morecells using CD34 + immunomagnetic cell separation systems. Experimental purging data based on human tumor at room temperature. The CD34 + enriched suspension tumors (n = 6) and multiple myeloma (n = 1) by using an (positive fraction) and cells from the starting cell suspenautomated continuous flow cell separator (COBE Spectra sion were assayed by immunofluorescence staining (see Apheresis System, Heimstetten, Germany or Baxter CSbelow). 3000Plus, Munich, Germany) before high-dose therapy protocols and autologous PBMNC reinfusion. All collected Flow cytometry cell products were microscopically free of tumor cells. According to our ethical board requirements, written infor-CD34 + cells were quantitated by flow cytometry. Aliquots med consent was obtained from every patient.
of 1 × 10 6 cells from the starting cell suspension as well as from the positive fraction were treated with 20 l (1 g) of phycoerythrin-conjugated anti-HPCA-2 antibody (clone Tumor cells 8G12; Becton Dickinson, Heidelberg, Germany) or of isoWe used three different human breast cancer cell lines type control antibody and kept at 4°C in the dark for 30 (HTB 26, HTB 131 and HTB 129) for the experiments and min. Stained cells were washed twice with phosphate buffone small-cell lung cancer cell line HTB 171 as a control ered saline (PBS), 0.5% bovine serum albumin (BSA) and for the flow cytometry characterization of the tumor cells.
0.01% sodium azide to remove unbound antibody. The pelAll cell lines were from the American Type Culture Colleclet was resuspended with 100 l propidium iodide (2 tion (Rockville, MD, USA). The breast cancer cell lines g/ml; P4 170, Sigma) in PBS and incubated at 4°C for were studied for expression of the CD34 antigen by flow 15 min in the dark. After two washing steps, cells were cytometry (FACScan, Becton Dickinson, Heidelberg, resuspended in 1 ml of the buffer and samples were Germany) (see below) and were found to be CD34-negative analyzed using a FACScan cytofluorometer (Becton (CD34 − ), HTB 171 being a CD34-positive (CD34 + ) control. Dickinson). Before exposure to immunomagnetic separation PBMNC Before tumor cells were taken for experiment, each cell were artificially contaminated with 1% (n = 5) or 10% (n line was tested for CD34 antigen in the same way. = 2) tumor cells from the chosen cell line. The tumor cell contamination was artifically adjusted to 1% or 10% of HTCA PBMNC to reach equal working conditions and to allow quantitating the contamination rate after CD34
+ cell selecTumor cell contamination of the CD34 + sample (positive tion by a tumor cloning assay (HTCA). fraction) after separation was evaluated by the number of colonies formed by tumor cells in human tumor cloning assays (HTCA) and compared with the number of colonies Isolex 50 formed in the starting suspension before separation. All cell lines were tested in a HTCA using mixtures of methylcelluFresh PBMNC were washed twice in RPMI 1640 medium (Seromed, Berlin, Germany) containing 1% human serum lose and agar (HTCAmix). A sample of the starting suspension before immunomagnetic separation as well as cells albumin (HSA; German Red Cross, Springe, Germany) (RPMI/HSA). The pellet was resuspended and contamifrom the positive fraction after separation were washed in the working buffer of the Isolex 50 system (see above), nated with the chosen tumor cell line (as described above). The cell suspension was incubated for 15 min at room temresuspended in an appropriate volume of RPMI 1640 medium and counted by trypan blue staining to yield a final perature in an appropriate volume of the working buffer (RPMI/HSA) supplemented with 0.5% human immunoconcentration of 3 × 10 6 viable cells/ml. Viability of the cells Ͼ80% was required before cells were taken for an globulin (Venimmun; Behring, Marburg, Germany) (RPMI/HSA/IG). Subsequently, cells were labelled with experiment. Methylcellulose solution was produced by boiling 0.5 l distilled water with 21 g methylcellulose (No. mouse anti-human CD34 antibody 9C5 (Baxter Healthcare, Deerfield, IL, USA) for 30 min at 4°C and slow end-over-M 0512; Sigma, Deisenhofen, Germany). 500 ml cold Iscove's modified Dulbeccos's medium (double concentrated; end rotation. Labelled cells were washed three times with RPMI/HSA/IG to remove unbound antibodies. Sterile para-GIBCO) was added to the methylcellulose after cooling down to 37°C. The mixture was kept in 3.6 ml aliquots at magnetic microbeads coated with sheep anti-mouse IgG1 (Fc) antibodies (SAM beads; Dynabeads M-450; Dynal, −20°C. Agar was made by boiling 3 g Difco agar (Agar Noble; Difco Lab, Detroit, MI, USA) in 100 ml distilled Oslo, Norway), which had been washed before in RPMI/HSA/IG three times, were mixed with the antibodywater for 30 min, and consecutively 3 ml of the boiling agar were added to 6 ml RPMI 1640 (37°C). The incubation labelled mononuclear cells at a 1:2 ratio and introduced into the disposable Isolex 50 chamber (Baxter). Beads and cells mixture was made up of 3.6 ml methylcellulose solution, 2.7 ml Hyclone FCS (Logan, UT, USA; Cat. No. A-1111-were incubated at 4°C and slow end-over-end rotation to allow rosette formation. Beads and rosetted target cells D), 0.06 ml mercaptoethanol (8.5 × 10 −3 mol/l mercaptoethanol in distilled water; Gibco, Eggenstein, Germany), were then collected by exposure to permanent magnets of the magnetic cell separator Isolex 50 (Baxter) and washed 0.3 ml cell suspension, 0.77 ml Iscove's modified Dulbecco's Medium (Gibco) and 1.63 ml agar/RPMI 1640 mixthree times with RPMI/HSA/IG. Unbound cells were col-ture. This incubation mixture was vortexed thoroughly and margin of our own experience growing colonies of a wide variety of human tumor cell lines in this assay without the kept in the dark at 37°C for 20 min to allow vanishing of bubbles. Consecutively, the mixture was seeded in 3.5 cm presence of PBMNC. 25 culture dishes (Nunc, Naperville, IL, USA) with an end concentration of 1 × 10 5 cells per dish. For each experiment Evaluation of immunomagnetic CD34 + cell selection depicted in the tables we have used six-fold assays. After 10 days at 37°C, pH 7.2, 5% CO 2 and high humidity colony
The efficiency of the immunomagnetic separation proformation and plating efficiency (PE, number of cells forcedure to select CD34 + cells from PBMNC was evaluated ming colonies/number of cells seeded, expressed as by applying the following definitions: percentage) were evaluated with an inverted microscope. Tumor cell colonies could be discriminated from colony Moreover, with the help of purity and the total count of cells in the positive fraction the expected number of remaining tumor cells and the expected depletion of tumor cells was calculated in each case and compared with the experimentally observed depletion where we defined:
The following gives a simple example of how to calculate the expected tumor cell depletion. Based on a cell suspension with 1 × 10 9 PBMNC including 1% tumor cell contamination and a following positive fraction of 1 × 10 7 cells with a purity of 90% after positive selection the remaining 10% mixed cell suspension with the same assumed rate of contamination provides 0.1% tumor cells for the total cell suspension. This results in a 3-log depletion of tumor cells.
To adjust this for clinical purposes it is important to consider the number of CD34 + cells necessary for reinfusion after high-dose therapy. A threshold value for reinfusion is 2 × 10 6 CD34 + cells/kg body weight of the patient. However, the CD34 + cell yield is variable between single harvests and positive selections. In order to ensure comparability of different selection experiments regardless of the b
CD34
+ cell yield of the experiment, 'yield corrected depletion' was calculated as follows: log depletion (yield corrected) = log yield + log depletion Statistical analysis evaluated by colony formation in human tumor cloning assay (HTCA). Thus, before tumor cell depletion by the Colony formation is compared by the 95% confidence interIsolex 50 was evaluated, tumor cells were tested in HTCA vals of PEs when different tumor cell numbers are seeded for variability of colony formation when seeded at different in HTCA. The 95% confidence interval of the PE in HTCA concentrations. In the experiments shown in Table 1 differwith the higher tumor cell number is nested within the 95% ent numbers of tumor cells from the breast cancer cell line confidence interval of the PE in HTCA with the lower HTB 26 were seeded in HTCA with PBMNC from fresh tumor cell number. leukapheresis products of the same day and PE was quantitated by tumor cell colony formation. In all three PBMNC conditions the 95% confidence interval of the PE in HTCA Results with the higher tumor cell number is within the 95% confidence interval of the PE in HTCA with the lower tumor The independence of plating efficiency (PE) from the numcell number. Thus, tumor cell colony formation does not ber of tumor cells seeded is crucial when tumor cell purging differ when the seeded tumor cell number varies. However, in immunomagnetic CD34
+ cell separation systems is PE of tumor cells seeded together with fresh PBMNC Tables 2 and 3 ). This is well The second group of experiments is shown in Table 3 . PBMNC were contaminated with 1% (n = 2) or 10% (n = Table 2 . Here, PBMNC were contaminated with 1% (n = 3) or 10% (n = 1) of tumor cells from the breast cancer 1) of tumor cells from the breast cancer cell lines HTB 131 and HTB 26 and the degree of purging is evaluated in cell lines HTB 26 and HTB 129. A low (Ϯ) ⌬ depletion value indicates that calculated depletion is correlating experiment Nos 5-7. In all three experiments the experimentally achieved tumor cell depletion is less efficient than approximately with the experimental data. In experiments Nos 1, 3 and 4 the experimental depletion only slightly the calculated data suggest which can be seen from the high negative ⌬ depletion values (−1.66, −0.82, −0.9 log steps). exceeds the calculated value which can be seen from the low positive ⌬ depletion value (+0.04, +0.21, +0.32 log In both Tables we have depicted tive fraction ('garbage') expressed as percentage of nummarking. 15, 16 However, purging is still considered experimental since prospective randomized studies are lacking. bers of tumor cells in the starting fraction (presort).
In experiment No. 7, PBMNC were taken from a patient This study evaluates the efficiency of purging tumor cells using a CD34
+ immunomagnetic cell separation system. By with multiple myeloma and it is possible that residual paraproteins may have influenced the normal behavior of tumor mathematically calculating the estimated tumor cell depletion in each experiment and comparing it with the cells during the separation procedure (eg by induction of tumor cell clumping), since in experiments Nos 1-3 HTB experimentally achieved data the behavior of three different tumor cell lines was controlled. In contrast to fluorescence 26 showed no evident deviation from the calculated degree of purging. On the other hand, this impression might be of assays in which dormant tumor cells not relevant for tumor self renewal are equally evaluated with clonogenic cells, minor importance and more experiments with identical cell lines might resolve this problem.
the HTCA is focussing on clonal tumor cell growth which is predictive for in vivo tumorigenicity. 29, 30 In consequence, Experiments Nos 5 and 6 are examples for a tumor cell line (HTB 131) in which still unknown reasons produce HTCA results may bear higher predictability for a potential relapse of the disease. a much lower purging effect than expected. In particular, membrane factors of HTB 131 could have some impact Standard calculations could be done under the assumption of a constant number of CD34 + cells in the harvest here since two experiments with PBMNC from different patients showed similar results. We therefore further anabefore and after CD34 + cell selection (yield of 100%). However, this is never the case since there is considerable lyzed the purged samples by cytomorphology. Figure 3 shows a phenomenon which we have observed frequently variability of CD34 + cell yield ranging from 21.0 to 85.2% in our experiments. This renders non-corrected depletion in these samples where tumor cells form the central cell of rosettes of hematopoietic CD34 + cells. values for tumor cells non-comparable. To evaluate clinical usefulness of a certain CD34 selection procedure for purgIn summary, using the Isolex 50 we achieved an efficient purging effect with a total median depletion of 2.75 log ing, yield-corrected depletion values have to be used for comparison as done in this study. With a yield corrected (range 1.55-3.69 log) or 2.38 log (range 1.48-3.15 log) for the yield corrected depletion in seven experiments. We depletion of 2.38 log tumor cells, the Isolex system not only provides high purity of CD34 + cells, but also efficient furthermore present evidence, that individual factors might negatively influence purging efficiency, so that mere mathdepletion of tumor cells.
In agreement with an earlier proposal, 31 our experiments ematical calculation can be incorrect.
show that the degree of tumor cell purging with a CD34 + cell selection method can only be exactly calculated mathematically if one assumes that the tumor cells are passive Discussion passengers during the separation procedure. Deviation of experimental from calculated purging data might be due to Purging of tumor cells not only from bone marrow but also from PBMNC prior to autologous reinfusion after highdifferent conditions involving plasma and disease of the patients as well as cytological characteristics of the condose chemotherapy may be essential since even in remission occult tumor cells are detected in bone marrow taminating tumor cells. Tumor cells may interact with CD34 + hematopoietic cells and PBMNC samples. [8] [9] [10] [11] [12] [13] [14] [15] [16] Purging may reduce the rate of tumor relapse in patients which is shown in retrospective or get trapped on the magnets themselves and thus are prevented from being washed out. These interactions can be studies. 10, 27, 28 The direct proof revealing residual tumor cells in autologous bone marrow transplants as being the assumed in experiments shown in Table 2 but they are not yet confirmed specifically. Interactions between stem cell origin of disease recurrence was obtained with genetic factor (SCF) and its receptor, the c-kit product, could be considered as candidates to cause rosetting of tumor cells by CD34 + hematopoietic cells as observed in this study. CD34-positivity of tumor cells is an additional concern if applying the method described here. There are rare tumors which can express the CD34 antigen such as testicular mixed germ cell tumors as recently published by Verbeek et al. 32 Especially when purging small-cell lung cancer autotransplants there is the need to examine co-expression of CD34 antigen since Köhler et al 33 found three out of 12 small-cell lung cancers of patients as being CD34-positive, whereas only one of 63 breast cancers expressed the CD34 antigen.
At the moment mainly three different purging methods are used clinically, which are still being intensively tested for methodological improvement and clinical relevance. Apart from positive stem cell selection (eg immunomagnetically with anti-CD34 antibodies as in this study) there are negative selection techniques in which tumor cells are elim- purging cycle was seen when using a cocktail of three dif-225-232.
ferent specific anti-tumor antibodies. 21 Anderson et al 
